Institute of Organ Transplantation, Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology, Key Laboratory of Organ Transplantation, Ministry of Education and Ministry of Health, Wuhan 430030, China
Highly sensitized patients experience an increased number of rejection episodes and have poorer graft survival rates; hence, sensitization is a significant barrier to both access to and the success of organ transplantation. This study reports our experience in kidney transplantation in highly sensitized patients. Fourteen patients with sensitization or high levels of panel-reactive antibodies (PRA) were studied. All patients were desensitized with pre-transplant intravenous immunoglobulin (IVIG)/plasmapheresis (PP) with or without rituximab and thymoglobulin induction therapy, combined with a Prograf/MMF/Pred immunosuppressive regimen. Of 14 patients, 10 showed good graft functions without acute rejection (AR) episodes. Acute cellular rejection in two patients was reversed by methylprednisolone. Two patients underwent antibody-mediated rejection; one was treated with PP/IVIG successfully, whereas the other lost graft functions due to the de novo production of donor-specific antibodies (DSA). Graft functions were stable, and there were no AR episodes in other patients. Conclusively, desensitization using PP/IVIG with or without rituximab increases the likelihood of successful live-donor kidney transplantation in sensitized recipients.
Vasilescu E R, Ho E K, Colovai A I, Vlad G, Foca-Rodi A, Markowitz G S, D’Agati V, Hardy M A, Ratner L E, Suciu-Foca N. Alloantibodies and the outcome of cadaver kidney allografts. Hum Immunol , 2006, 67(8): 597-604 doi: 10.1016/j.humimm.2006.04.012 pmid:16916655
2
Gebel H M, Moussa O, Eckels D D, Bray R A. Donor-reactive HLA antibodies in renal allograft recipients: considerations, complications, and conundrums. Hum Immunol , 2009, 70(8): 610-617 doi: 10.1016/j.humimm.2009.04.012 pmid:19375473
3
Flores-Gama F, Mondragón-Ramírez G A, Bochicchio-Riccardelli T. Desensitization and renal transplant: plasmapheresis/IVIG standard dose in patients with high immunological risk. Cir Cir , 2009, 77(5): 369-374 pmid:19944025
4
Varma P P, Hooda A K, Kumar A, Singh L. Highly successful and low-cost desensitization regime for sensitized living donor renal transplant recipients. Ren Fail , 2009, 31(7): 533-537 doi: 10.1080/08860220903001861 pmid:19839846
5
Kim S M, Lee C, Lee J P, Kim E M, Ha J, Kim S J, Park M H, Ahn C, Kim Y S. Kidney transplantation in sensitized recipients; a single center experience. J Korean Med Sci , 2009, 24 (Suppl): S143-S147 doi: 10.3346/jkms.2009.24.S1.S143 pmid:19194544
6
Faenza A, Fuga G, Bertelli R, Scolari M P, Buscaroli A, Stefoni S. Hyperimmunized patients awaiting cadaveric kidney graft: is there a quick desensitization possible? Transplant Proc , 2008, 40(6): 1833-1838 doi: 10.1016/j.transproceed.2008.05.078 pmid:18675064
7
Segev D L, Gentry S E, Melancon J K, Montgomery R A. Characterization of waiting times in a simulation of kidney paired donation. Am J Transplant , 2005, 5(10): 2448-2455 doi: 10.1111/j.1600-6143.2005.01048.x pmid:16162194
8
Claas F H, Doxiadis I I. Management of the highly sensitized patient. Curr Opin Immunol , 2009, 21(5): 569-572 doi: 10.1016/j.coi.2009.07.010 pmid:19682882
9
Yoon H E, Hyoung B J, Hwang H S, Lee S Y, Jeon Y J, Song J C, Oh E J, Park S C, Choi B S, Moon I S, Kim Y S, Yang C W. Successful renal transplantation with desensitization in highly sensitized patients: a single center experience. J Korean Med Sci , 2009, 24 (Suppl): S148-S155 doi: 10.3346/jkms.2009.24.S1.S148 pmid:19194545
10
Fourtounas C, Mouzaki A, Vlachojannis J G. Desensitization during renal transplantation. N Engl J Med , 2008; 359: 1731-1732
11
Jordan S C, Vo A, Tyan D, Toyota M. Desensitization therapy with intravenous gammaglobulin (IVIG): applications in solid organ transplantation. Trans Am Clin Climatol Assoc , 2006, 117: 199-211 , discussion 211 pmid:18528474
12
Jordan S. IVIG vs. plasmapheresis for desensitization: which is better? Am J Transplant , 2006, 6(7): 1510-1511 doi: 10.1111/j.1600-6143.2006.01393.x pmid:16827849
13
Glotz D, Antoine C, Julia P, Suberbielle-Boissel C, Boudjeltia S, Fraoui R, Hacen C, Duboust A, Bariety J. Desensitization and subsequent kidney transplantation of patients using intravenous immunoglobulins (IVIg). Am J Transplant , 2002, 2(8): 758-760 doi: 10.1034/j.1600-6143.2002.20809.x pmid:12243496
14
Akalin E, Dinavahi R, Friedlander R, Ames S, de Boccardo G, Sehgal V, Schr?ppel B, Bhaskaran M, Lerner S, Fotino M, Murphy B, Bromberg J S. Addition of plasmapheresis decreases the incidence of acute antibody-mediated rejection in sensitized patients with strong donor-specific antibodies. Clin J Am Soc Nephrol , 2008, 3(4): 1160-1167 doi: 10.2215/CJN.05321107 pmid:18337549
15
Stegall M D, Gloor J, Winters J L, Moore S B, Degoey S. A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am J Transplant , 2006, 6(2): 346-351 doi: 10.1111/j.1600-6143.2005.01178.x pmid:16426319
16
Vo A A, Lukovsky M, Toyoda M, Wang J, Reinsmoen N L, Lai C H, Peng A, Villicana R, Jordan S C. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med , 2008, 359(3): 242-251 doi: 10.1056/NEJMoa0707894 pmid:18635429
17
Munoz A S, Rioveros A A, Cabanayan-Casasola C B, Danguilan R A, Ona E T. Rituximab in highly sensitized kidney transplant recipients. Transplant Proc , 2008, 40(7): 2218-2221 doi: 10.1016/j.transproceed.2008.07.046 pmid:18790197
18
Buehrig C K, Lager D J, Stegall M D, Kreps M A, Kremers W K, Gloor J M, Schwab T R, Velosa J A, Fidler M E, Larson T S, Griffin M D. Influence of surveillance renal allograft biopsy on diagnosis and prognosis of polyomavirus-associated nephropathy. Kidney Int , 2003, 64(2): 665-673 doi: 10.1046/j.1523-1755.2003.00103.x pmid:12846764
